Urol. praxi. 2025;26(2):102-107 | DOI: 10.36290/uro.2025.046

Prostate cancer - interaction potential of used drugs

PharmDr. Roman Goněc¹, PharmDr. Vojtěch Ondra^{1, 2}, doc. PharmDr. Jan Juřica, Ph.D.^{1, 2, 3}

¹ Ústavní lékárna, Masarykův onkologický ústav, Brno

² Ústav farmakologie a toxikologie, Farmaceutická fakulta, Masarykova univerzita, Brno

³ Farmakologický ústav, Lékařská fakulta, Masarykova univerzita, Brno

Advances in the treatment of prostate cancer in the last years have made it possible to cnsider prostate cancer a chronic disease, particulary in older patients. These patients are usually polymorbid and with increasing number of drugs they use, the risk of interactions also rises. Such interactions could lead to increased toxicity or reduced effect of anti-cancer drugs. However, mainly enzalutamide and apalatumide can significantly reduce the effectiveness of many commonly used drugs, and it is essential that the physicians are well-informed about these risks. In Czech Republic, enzalutamide, apalutamide, darolutamide, abiraterone, talazoparib, olaparib, and niraparib are not prescribed outside cancer centers and due to different classification do not appear in the patient's electronic drug record. Consultation with a clinical pharmacist before starting treatment may help to reduce the risk of drug interactions and to choose the most appropriate treatment.

Keywords: prostate cancer, drug interaction.

Accepted: May 19, 2025; Published: June 26, 2025  Show citation